Ticagrelor vs clopidogrel on vein graft patency in patients with diabetes undergoing coronary artery bypass grafting

BACKGROUNDPatients with type 2 diabetes mellitus (T2DM) undergoing coronary artery bypass grafting (CABG) are at high risk of saphenous vein graft (SVG) failure.The optimal antiplatelet therapy for maintaining SVG patency in this population remains uncertain. AIMTo investigate whether ticagrelor plus aspirin is associated with better 5-year SVG patency than clopidogrel plus aspirin in patients with T2DM who undergo CABG. CONCLUSIONAmong 5-year survivors with T2DM who underwent CABG, ticagrelor plus aspirin was associated with better 5-year SVG grade A patency than clopidogrel plus aspirin.This is an uncontrolled observational association, and the estimand is limited to patients who survived to the 5-year CTA.The MACE and BE are inconclusive.These findings do not establish causality, superiority, or equivalent safety.Adequately powered, multicenter, prospective randomized controlled trials are required.

Authors

Institutions

Publication Details

Journal
World Journal of Diabetes
Published
2026-11-18
DOI
https://doi.org/10.4239/wjd.125765
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ticagrelor vs clopidogrel on vein graft patency in patients with diabetes undergoing coronary artery bypass grafting

Keng Zhong, Guanxin Zhang, Jiao-Na Qiu, Qing Xue et al.
World Journal of Diabetes
Antiplatelet Therapy and Cardiovascular Diseases
article

Ticagrelor vs clopidogrel on vein graft patency in patients with diabetes undergoing coronary artery bypass grafting

Keng Zhong, Guanxin Zhang, Jiao-Na Qiu, Qing Xue, Zhi-Min Zhao, Jie Lu, Xing-Li Fan, Wen-Wen Li, Rui-Jun Yuan
article en

Abstract

BACKGROUNDPatients with type 2 diabetes mellitus (T2DM) undergoing coronary artery bypass grafting (CABG) are at high risk of saphenous vein graft (SVG) failure.The optimal antiplatelet therapy for maintaining SVG patency in this population remains uncertain. AIMTo investigate whether ticagrelor plus aspirin is associated with better 5-year SVG patency than clopidogrel plus aspirin in patients with T2DM who undergo CABG. CONCLUSIONAmong 5-year survivors with T2DM who underwent CABG, ticagrelor plus aspirin was associated with better 5-year SVG grade A patency than clopidogrel plus aspirin.This is an uncontrolled observational association, and the estimand is limited to patients who survived to the 5-year CTA.The MACE and BE are inconclusive.These findings do not establish causality, superiority, or equivalent safety.Adequately powered, multicenter, prospective randomized controlled trials are required.

World Journal of Diabetes
Second Military Medical University (CN), Changhai Hospital (CN)
Shanghai Municipal Health Commission, National Natural Science Foundation of China, Changhai Hospital of Shanghai
Good health and well-being
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon